HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Johnson, P. W.M. Articles by Davies, A. J. Search for Related Content PubMed PubMed Citation Articles by Johnson, P. W.M. Articles by Davies, A. J. Social Bookmarking                   What's this?

Primary Mediastinal B-Cell Lymphoma

Correspondence: Peter W.M. Johnson, MD, Cancer Research UK Clinical Centre, University of Southampton, Somers Cancer Research Bldg. MP 824, Southampton, S016 6YD, UK; Phone: +44-2380-796186; Fax: +44-2380-795152; e-mail: johnsonp{at}southampton.ac.uk

Abstract

Primary mediastinal B-cell lymphoma is a discrete clinicopathologic entity. Molecular analysis reveals it to be distinct from other types of large B-cell lymphoma, and retrospective analysis suggests that it may respond better to multi-agent chemotherapy regimens than to the more commonly used CHOP. The addition of rituximab may mitigate such differences, and may also diminish the role of consolidation radiotherapy, which is often used to treat residual mediastinal masses. For the future the role of FDG-PET scanning requires prospective examination, and it is hoped that this may allow the de-escalation of treatment if it can be shown to yield reliable prognostic information. The relative rarity of this type of lymphoma necessitates international collaboration in clinical trials, with a prospective clinicopathologic study, IELSG 26, already underway.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?